SEC Form 3 filed by new insider Chuang Hao-Yuan
$BLTE
Biotechnology: Pharmaceutical Preparations
Health Care
| FORM 3 | UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
| |||||||||||||||
1. Name and Address of Reporting Person*
(Street)
(Country) | 2. Date of Event Requiring Statement
(Month/Day/Year) 03/18/2026 | 3. Issuer Name and Ticker or Trading Symbol
BELITE BIO, INC [ BLTE ] | |||||||||||||||
| 3a. Foreign Trading Symbol
| 5. If Amendment, Date of Original Filed
(Month/Day/Year) | ||||||||||||||||
| 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
| 6. Individual or Joint/Group Filing (Check Applicable Line)
| ||||||||||||||||
| Table I - Non-Derivative Securities Beneficially Owned | |||
|---|---|---|---|
| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
| American depositary share(1) | 100,000 | D | |
| Ordinary Share | 195,264 | D | |
| Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
|---|---|---|---|---|---|---|---|
| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
| Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
| Stock Option (right to buy) | (2) | 12/22/2030 | Ordinary Shares | 144,868 | $0.4386 | D | |
| Stock Option (right to buy) | (3) | 04/17/2032 | Ordinary Shares | 26,112 | $6 | D | |
| Stock Option (right to buy) | (4) | 07/16/2033 | Ordinary Shares | 120,834 | $14.45 | D | |
| Stock Option (right to buy) | (5) | 08/28/2034 | Ordinary Shares | 250,000 | $48.46 | D | |
| Stock Option (right to buy) | (6) | 02/11/2035 | Ordinary Shares | 200,000 | $54.88 | D | |
| Stock Option (right to buy) | (7) | 10/06/2035 | Ordinary Shares | 40,000 | $77.4 | D | |
| Stock Option (right to buy) | (8) | 10/27/2035 | Ordinary Shares | 80,000 | $93.02 | D | |
| Stock Option (right to buy) | (9) | 01/08/2036 | Ordinary Shares | 150,000 | $158.36 | D | |
| Explanation of Responses: |
| 1. Each American depositary share represents one ordinary share, par value US$0.0001 per share, of the Issuer. |
| 2. The option to purchase 144,868 ordinary shares had vested prior to March 18, 2026. |
| 3. The option to purchase 26,112 ordinary shares had vested prior to March 18, 2026. |
| 4. The option to purchase 100,000 ordinary shares had vested prior to March 18, 2026. The option shall vest as to the remaining 20,834 ordinary shares in five monthly equal and continuous installments at the end of each month from March 2026 to July 2026, subject to continued service to the Issuer on each such date. |
| 5. The option shall vest as to 250,000 ordinary shares in 36 equal and continuous monthly installments for each full month of services completed following August 29, 2024, subject to continued service to the Issuer on each such date. |
| 6. The option shall vest as to 200,000 ordinary shares in 36 equal and continuous monthly installments for each full month of services completed following February 12, 2025, subject to continued service to the Issuer on each such date. |
| 7. The option to purchase 40,000 ordinary shares had vested prior to March 18, 2026. |
| 8. The option to purchase 80,000 ordinary shares had vested prior to March 18, 2026. |
| 9. The option shall vest (i) as to 50,000 ordinary shares on January 9, 2027, (ii) as to 50,000 ordinary shares on January 9, 2028, and (iii) as to 50,000 ordinary shares on January 9, 2029. |
| Remarks: |
| Exhibit 24 - Power of Attorney |
| /s/ Hao-Yuan Chuang | 03/18/2026 | |
| ** Signature of Reporting Person | Date | |
| Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
| * If the form is filed by more than one reporting person, see Instruction 5 (b)(v). | ||
| ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
| Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
| Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. | ||
| * Form 3: SEC 1473 (03-26) | ||